Author(s)

S. A. Mangar

Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, UK.

The benefit of elective nodal irradiation (ENI) in combination with androgen deprivation therapy in high risk localized node negative prostate cancer has yet to be clearly defined. The potential gains in local control have been offset by the increased toxicity associated with pelvic radiotherapy, and recognition that historically the only trials to demonstrate a survival advantage in this group have been with androgen deprivation therapy. This review article considers the impact of pivotal randomized clinical trials conducted over the last thirty years on routine clinical practice, and how modern techniques may help to redefine radiotherapy as a necessary component for this group of patients.

Prostate Cancer, Pelvic Radiotherapy, Clinical Trials, Androgen Deprivation Therapy, IMRT

Mangar, S. (2017) The Re-Emerging Role of Elective Pelvic Nodal Irradiation in High-Risk Node Negative Prostate Cancer. Journal of Cancer Therapy, 8, 1135-1148. doi: 10.4236/jct.2017.813097.